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Abstract 
Purpose: A randomized clinical trial examined whether dexamethasone administration 
prior to odansetron followed by etoposide and carboplatin infusions, and single-
nucleotide polymorphisms (SNPs) of CYP3A4, CYP3A5 and MDR1 genes could modify 
etoposide pharmacokinetics in pediatric patients. 
Methods: Patients, 67 children, aged 14 weeks to 16.7 years, were treated for various 
malignancies and received  either 3- or 5-days courses of etoposide and carboplatin: 
these two drugs were always administered after odansetron infusion but combined or not 
to dexamethasone 5 mg/m²/day 30 min prior to etoposide infusion. Population 
pharmacokinetics was modelled using a non linear mixed effect model program (Monolix 
version 31s). 
Results: Etoposide pharmacokinetics was ascribed to a 2-compartment model. The 
most significant covariate effect was bodyweight (BW), so the parameters were 
standardized to a 70 kg BW using the allometric ¾ or 1 power model for clearance (CL, 
Q) or volume terms (V), respectively. The population means for clearance and central 
volume of distribution were 2.05 L/h/70kg and 9.21 L/70kg with the corresponding 
between-subject variabilities, 0.26 and 0.28. Dexamethasone treatment had no effect  on 
CL, either at the first or last administration occasion. CYP3A and MDR1 examined SNPs 
had no significant effect. 
Conclusion:. Pharmacokinetics of etoposide was influenced by BW on an allometric 
basis in this pediatric population. Dexamethasone did not influence etoposide 
pharmacokinetics during these 3 to 5 days courses.  These results should allow a better 
individualisation of etoposide dosing in children.
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Introduction 
 Chemotherapy combining etoposide and carboplatin has been proven effective in 
the treatment of children with various cancer diseases, including medulloblastoma (1), 
neuroblastoma (2), nephroblastoma (3) and  retinoblastoma (4).  This highly potent 
chemotherapy is often associated to nausea and vomiting in children during and after the 
treatment period. The prevention of these adverse effects in children usually includes a 
combination of dexamethasone and odansetron (5). However, as etoposide is O-
demethylated by cytochromes P450 (CYP) CYP3A4 and CYP3A5, dexamethasone could 
influence  etoposide elimination via some effects on these CYPs (6). Moreover, single-
nucleotide polymorphisms (SNPs) in CYP3A4 and CYP3A5 genes may modify enzymatic 
activity and then influence etoposide drug elimination rate. Indeed, a decrease of 
CYP3A4 activity has been associated with a SNP in the 5’-regulatory region of the 
CYP3A4 gene (-392A>G), named CYP3A*1B. Besides, the frequent SNP in intron 3 of 
the CYP3A5 gene (CYP3A5*3) results in an inactive truncated protein (7,8). Furthermore, 
as etoposide is a substrate of the P-glycoprotein, encoded by the MDR1 gene, MDR1 
gene SNPs could also modify etoposide disposition (9).  
The objectives of this study were then to develop a population pharmacokinetic 
model for etoposide in pediatric patients and to examine a possible dexamethasone 
effect on etoposide elimination,  including the research of other covariates as well as the 
effects of the SNPs of CYP3A4, CYP3A5 and MDR1 genes on etoposide clearance. 
 
Methods 
This randomized open clinical trial examined whether dexamethasone could modify 
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etoposide pharmacokinetics in pediatric patients. All children had a documented cancer 
and were randomly allocated to either the single odansetron or the combined 
odansetron-dexamethasone antiemetic therapy group. This study was approved by the 
regional ethics committee and written consent had to be obtained from the parents 
before inclusion. Appropriate information had to be given to patients according to their 
age and assent of the oldest children and adolescents was necessary before study 
initiation.  Patients aged 3 months to 16 years with a bodyweight greater than 4.5 kg and 
receiving the etoposide/carboplatin chemotherapy were eligible. 
Patients received a 1-h etoposide infusion followed by a 1-h carboplatin infusion 
on 3 or 5 successive days (three-day chemotherapy: etoposide 150 mg/m²/day etoposide 
and 200 mg/kg/day carboplatin, except for children < 1 year old or < 10 kg,  5 mg/kg/day 
etoposide and 6.7 mg/kg/day carboplatin ; five-day chemotherapy: etoposide 100 
mg/m²/day etoposide and 160 mg/m²/day carboplatin, except for children < 1 year old or 
< 10 kg,  3.3 mg/kg/day etoposide and 5.3 mg/kg/day carboplatin). Thirty minutes prior to 
chemotherapy, patients received odansetron 5 mg/m²/day combined or not to 
dexamethasone 5 mg/m²/day. 
 For most patients, two pharmacokinetic evaluations took place on the first and 
last day of chemotherapy.  Four sampling times per evaluation were randomly drawn 
from the following set : 5, 15, 30 min, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 h following the end of 
infusion. Blood samples were immediately centrifuged to yield plasma. Etoposide was 
essayed in 100 µL plasma samples by high-performance liquid chromatography with 
teniposide as internal standard and fluorometric detection according to a validated 
method (10). The limit of quantification was 0.1 mg/L.  
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 DNA extraction and genotyping. Blood samples were collected for genotyping after 
obtaining a written informed consent by the parents. Genomic DNA was extracted from 
peripheral blood leukocytes using the Blood Mini Kit DNA (Qiagen, Courtaboeuf, France) 
according to standard protocols, and stored at -80°C until use.  For the SNPs 6986A>G 
of CYP3A5 gene (CYP3A5*3; rs776746), 2677G>T/A (exon 21; rs2032582) and 
3435C>T (exon 26; rs1045642) of MDR1 gene, alleles were determined by using Taq 
Man® Assay Reagents and probes for allelic discrimination (TaqMan® SNP Genotyping 
Assays,  Applied Biosystems, Courtaboeuf, France) with a 7900HT Applied Biosystems 
thermal cycler. For the SNP –392A>G of CYP3A4 (CYP3A4*1B; rs2740574), primers 
and probe set were designed using the custom TaqMan® SNP Genotyping Assays 
Service (Applied Biosystems). Sequences are available upon request. 
 
Population pharmacokinetic modelling. Data were analysed using the nonlinear mixed 
effect modelling software program Monolix version 31s (11) 
(http://wfn.software.monolix.org). Parameters were estimated by computing the maximum 
likelihood estimator of the parameters without any approximation of the model (no 
linearization) using the stochastic approximation expectation maximization (SAEM) 
algorithm combined to a MCMC (Markov Chain monte Carlo) procedure. The number of 
MCMC chains was fixed to 5 for all estimations. A proportional model was used to 
describe the residual variability, and the between-subject variabilities (BSV) were 
ascribed to an exponential model. Parameter shrinkage was calculated as {1-
sd(eta)/omega}, where sd(eta) and omega are the standard deviation of individual eta 
parameters and the population model estimate of the BSV respectively. For the SNPs of 
CYP3A4, CYP3A5 and MDR1 genes, all the genotypes effects (9 parameters) were 
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estimated together relative to the wild type (baseline CL). Then at each successive step 
the genotype effect with the less significant parameter (with the greatest p value) was 
removed. Moreover, the Likelihood Ratio Test  (LRT) including the log-likelihood, the 
Akaike information criterion (AIC) and the bayesian information criterion (BIC) was used 
to test different hypotheses regarding the final model, covariate effect on 
pharmacokinetic parameter(s), residual variability model (proportional versus proportional 
plus additive error model), structure of the variance-covariance matrix for the BSV 
parameters. Diagnostic graphics and other statistics were obtained using the R program 
(12). 
 
Results 
From the 67 patients investigated, 566 time-plasma concentrations were available 
for analysis. Nine concentrations were reported below the limit of quantification (BLQ) 
and considered as left-censored data in the modelling process. Patients characteristics 
are summarized in Table 1. 
A two-compartment open model adequately described etoposide data. BSV was 
estimated for all structural parameters with a covariance term between the clearance 
(CL) and central volume of distribution (Vc). Residual variability was described by a 
proportional error model. At this step, CL was 0.69 L/h (relative standard error, rse 7%) 
per a mean 20.6 kg  BW and the corresponding BSV was 53% (rse 2%).  
The main covariates effects on all pharmacokinetic parameters were BW and age 
(Fig. 1), so the pharmacokinetic parameters were allometrically normalized for BW to a 
70 kg individual as follows,  
Pi = PTYPICAL x (BWi/70)
PWR
, 
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where  i denotes the ith individual. The PWR exponents  were ¾ and 1 for the 
clearance and volume terms respectively. This significantly decreased all BSV estimates 
(BSV of CL decreased from 53% to 28%) and improved the predictive performance of 
the model (observed concentrations versus model predicted concentrations). Thereafter, 
an additional age effect was investigated using a sigmoid Emax model relating the post-
menstrual age (PMA = post-natal age + 40 weeks) to a fractional value for mature 
clearance, FPMA = PMA
h
/(PMA50
h
+PMA
h
), where PMA50 is the PMA at which FPMA=0.5 
and h is the Hill coefficient. This did not improve the model, and the PMA50 and h 
estimates were not significant with much more than 50% relative standard errors. The 
effect of age was finally removed by the BW allometric scaling.  
The dexamethasone effect on etoposide CL was allowed to be different on the first 
and second occasion (3 to 5 days later). Without dexamethasone (control treatment) 
etoposide CL estimates on the 1
st
 and 2
nd
 occasions were not significantly different. 
Thereafter, there was no significant difference between etoposide CL estimates without 
or with a previous infusion of dexamethasone, on the 1
st
 or 2
nd
 occasion, the CL 
variations relative to the control were lower than 2%. 
Table 2 shows the distribution of CYP3A4, CYP3A5 and MDR1  genotypes in the 
67 children. No significant effects of CYP3A4, CYP3A5 or MDR1 gene SNPs on 
etoposide pharmacokinetics were observed. There was a trend in CL  increase, +9%, in 
patients with the CYP3A5*1*3 genotype (Wald test, p=0.09, n=10 patients in this group).  
Table 3 summarizes the final population pharmacokinetic estimates. Most of the 
parameters were well estimated with low relative standard errors. The empirical Bayesian 
estimate shrinkages were generally low, only the peripheral pharmacokinetic parameters, 
Q and Vp had shrinkage estimates between 20 and 25%.  
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The results of the visual predictive check (VPC)  are depicted in Fig. 2. The 
patients received generally a dose normalised by size. Therefore the VPCs were finally 
stratified according to the first and last infusion, respectively. For all  groups, the 
observed concentrations were centered about the model-predicted median and the 
proportion of observations out of the model-predicted 5
th
 and 95
th
 percentile curves were 
not significantly different from 10%. 
Based on individual etoposide clearance estimates and drug dosages, the mean 
total etoposide exposure (area under the curve or AUC) was 371 (± 94) or 474 (±127) 
mg.h/L for the 3- or 5-day chemotherapy respectively (significant difference, Kruskal-
Wallis rank sum test  p = 0.0003). Given the significant relationship between clearance 
and bodyweight, the etoposide dosage targetting these drug exposures, 371 and 474 
mg.h/L, were compared to the actual drug exposure. Figure 3 shows the great variability 
achieved in etoposide exposure with the actual dosage, particularly for the smallest, 
youngest, patients and the difference between the actual drug dosage and a candidate 
drug dosage aimed to target the same AUC for each therapeutic modality (Dose = 
2.05.(BW/70)
3/4
 .AUCtarget). 
 
Discussion 
The pharmacokinetics of plasma etoposide in pediatric patients was satisfactorily 
described by an open two-compartmental model with linear elimination. The 
administration of dexamethasone in addition to odansetron as antiemetic therapy, prior to  
etopside-carboplatin infusions, had no significant effect on etoposide CL. The etoposide 
CL estimate, 2.05 L/h/70 kg  was close to previously reported estimates in adult patients, 
1.8 L/h (13)  or 2.65 L/h (14), supporting the BW allometric scaling  of pharmacokinetic 
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parameters. Moreover in a population of 18 infants aged 2.5 – 14 months (median 10 
months), the estimated CL was 6.3 mL/min/8 kg or 0.38 L/h/8 kg (15), which according to 
the BW allometric scaling will be 0.38 x (70/8)
3/4
 = 1.92 L/h/ 70kg.  Also, in 45 pediatric 
patients aged 0.5 – 17.7 years, the estimated CL was 17.1 or 17.6 mL/min/m² according 
to two age groups, corresponding  to 1.84 or 1.90 L/h/ 1.8 m² (16). 
In developmental pharmacokinetic approaches, an effect of age on CL could 
generally be observed in addition to the BW allometric scaling (17). This age effect 
explains a part of the CL maturation that is not dependent upon BW. However, in 
pediatric population, the age-related effect independent of size effect cannot always be 
established. The reasons are generally a too small sample size or a lack of data in age 
group below 1 year, in which age group the age-related CL maturation is very fast. In our 
study, only 8 patients were less than 1 year old, and only 2 were less than 6 months old. 
No effect of prior dexamethasone administration on this short chemotherapy time 
period was observed. Kishi et al. (18) observed an increase in etoposide CL after a 29-
day period of prednisone treatment, but could not definitively attribute this effect to an 
induction of CYP3As. Since several days of drug exposition are required to observe 
induction of CYPs and transporters (involving transcription and protein traduction), the 3 
to 5 days exposition to dexamethasone in the present study appears to be too short to 
increase etoposide clearance. 
Among other covariates,  the CYP3A5*1*3 genotype was associated to a trend in 
CL increase (not significant). The CYP3A4 *1A*1B and *1B*1B genotypes included only 
4 and 2 patients, respectively, and did not allow to show any significant CL changes in 
this population of 67 children. Finally, the lack of effect of MDR1 gene SNPs are in 
accordance with the results of Tran et al. for docetaxel disposition (19). Conversely, Kishi 
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et al. showed that MDR1 exon 26 CC genotype predicted higher day etoposide 
clearance. This discrepancy may be associated to a higher statistical power (greater 
number of patients) in their study (18). 
Finally, there was a great variability in the achieved etoposide exposure, 
particularly in the youngest patients. This variability in exposure could be decreased if the 
drug dosage was aimed to target a particular exposure value, according to the patient 
clearance expected from bodyweight. 
In conclusion, pharmacokinetics of etoposide was influenced by bodyweight on an 
allometric basis in this pediatric population. Dexamethasone did not influence etoposide 
pharmacokinetics. These results should allow a better individualisation of etoposide 
dosing in children and the safe use of dexamethasone as an anti-emetic drug when 
etoposide is combined to carboplatin. 
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Table 1 
Characteristics of the 67 pediatric patients 
 
Item n Mean Median Range  
Age (year) 67 5.35 3.52 0.27 – 16.7 
Bodyweight (kg)   20.6 15 5.3 - 66 
Height (cm)  105 100 60 - 172 
Serum creatinine (µM)  48 79 15 - 650 
Total bilirubin (µM)  6.7 6.0 2 - 17 
Tumor type     
-medulloblastoma 18    
-neuroblastoma 26    
-nephroblastoma 7    
-retinoblastoma 5    
-miscellanous 11    
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Table 2 
Genotypes of CYP3A4, CYP3A5 and MDR1 in 67 pediatric patients 
 
 CYP3A5*3*3 CYP3A5*1*3  CYP3A5*1*1 
CYP3A4 *1A*1A 55 6 0 
CYP3A4 *1A*1B 1 3 0 
CYP3A4 *1B*1B 0 1 1 
    
 MDR1 3435 CC MDR1 3435 CT MDR1 3435 TT 
MDR1 2677 GG 16 5 2 
MDR1 2677 GA 1 0 0 
MDR1 2677 GT 1 26 7 
MDR1 2677 TT 0 2 7 
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Table 3 
Parameter estimates of the final etoposide population model in 67 pediatric patients (14 
weeks – 16.7 years). Parameters are normalized after a 70 kg patient according to 
allometric scaling 
Parameter Covariate effect Estimate (%rse) BSV (%rse) [shrinkage] 
CL70 ( L/h/70kg)  CL = CL70  (BWi/70)
3/4
 2.05 (4) 0.27 (9) [0.04] 
Vc70 (L/70kg)   Vc = CL70 (BWi/70)
1
 9.3 (5) 0.28 (15) [0.19] 
Q70 (L/h/70 kg)  Q = CL70 (BWi/70)
3/4
 0.68 (15) 0.96 (10) [0.21] 
Vp70 (L/70 kg)  Vp = CL70 (BWi/70)
1
 5.7 (8) 0.53 (13) [0.23] 
Residual 
variability 
NA Proportional 0.222 (4) [0.12] 
Key : %rse, percent relative standard error ; BSV, between-subject variability ; CL and Q, 
elimination and intercompartmental clearances; Vc and Vp, central and peripheral 
volumes of distribution; the subscript “70” indicates the parameter estimates are 
normalized to a 70 kg bodyweigth ; BWi, individual bodyweight. The correlation between 
CL and Vc BSVs is 0.89. Accordingly, the expected CL for a patient weighing 15 kg is 
2.05x(15/70)
3/4
 = 0.75 L/h. 
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Figure legends  
Fig 1 
Relationships between the empirical Bayes estimates (EBE) of etoposide clearance, in 
L/h, from the basic model and bodyweight (BW in kg) and age (years) in 67 pediatric 
patients. The dashed lines are drawn after a spline function. The median of EBE 
clearance estimates is 0.74 L/h (range 0.21 – 1.84). 
 
Fig 2 
Visual predictive check for the final etoposide population model in 67 children (14 weeks 
– 17 years). Panels ADM.1 and ADM.2 denote the first etoposide or the second 
etoposide administration. The solid lines lines stand for the median, 5
th
 and 95
th
 
percentiles of the simulated concentrations from the final model. The dashed lines lines 
stand for the median, 5
th
 and 95
th
 percentiles of the observed concentrations. Symbols * 
denote the concentrations reported below the limit of quantification. 
 
Fig 3 
Etoposide exposure (AUC) achieved on a 3-day or 5-day chemotherapy (TOP) and 
etoposide total dose on a 3-day or 5-day chemotherapy : (o, solid line) actual dose 
received or (+, dashed line) dose based on a target AUC (BOTTOM), versus patient 
bodyweight (BW). Etoposide exposure is determined as AUC = (total dose)/(individual 
clearance) and the dose based on a target AUC is determined as D = 2.05.(BW/70)
3/4
 . 
AUC  (371 and 474 mg.h/L for the 3-day or 5-day chemotherapy). The lines are drawn 
after a spline function. 
 
